Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more
Galapagos NV - Asset Resilience Ratio
Galapagos NV (GLPGF) has an Asset Resilience Ratio of 85.02% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Galapagos NV's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Galapagos NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.51 Billion | 85.02% |
| Total Liquid Assets | $3.51 Billion | 85.02% |
Asset Resilience Insights
- Very High Liquidity: Galapagos NV maintains exceptional liquid asset reserves at 85.02% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Galapagos NV Industry Peers by Asset Resilience Ratio
Compare Galapagos NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Galapagos NV (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Galapagos NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 73.83% | $3.05 Billion | $4.14 Billion | -6.90pp |
| 2023-12-31 | 80.73% | $3.52 Billion | $4.36 Billion | +4.99pp |
| 2022-12-31 | 75.74% | $3.59 Billion | $4.73 Billion | +28.18pp |
| 2021-12-31 | 47.56% | $2.47 Billion | $5.19 Billion | -5.37pp |
| 2020-12-31 | 52.93% | $3.03 Billion | $5.72 Billion | -11.65pp |
| 2019-12-31 | 64.58% | $3.92 Billion | $6.07 Billion | +13.62pp |
| 2018-12-31 | 50.96% | $733.54 Million | $1.44 Billion | +50.73pp |
| 2017-12-31 | 0.23% | $2.91 Million | $1.29 Billion | -0.09pp |
| 2016-12-31 | 0.32% | $3.45 Million | $1.08 Billion | -1.57pp |
| 2015-12-31 | 1.89% | $8.37 Million | $442.51 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $270.47 Million | -- |